UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PADAGIS US LLC
Petitioner,

v.

NEURELIS, INC.
Patent Owner.

Case IPR2025-00466
Patent 11,793,786

PETITIONER'S UPDATED EXHIBIT LIST[1]

[1] Submission of additional exhibits 1105-1107 authorized pursuant to the Board's email sent on June 9, 2026.

LIST OF EXHIBITS

Exhibit No.	Description
1001	U.S. Patent No. 11,793,786, Administration Of Benzodiazepine Compositions, filed April 12, 2021 ("'786 Patent")
1002	File History for 11,793,786 Patent, Ser. No. 17/228,514 ("'786 FH")
1003	U.S. Patent No. 11,241,414, Administration of Benzodiazepine Compositions, filed May 27, 2021 ("'414 Patent")
1004	File History for 11,241,414, Ser. No. 17/332,800 ("'414 FH")
1005	Non-Provisional Patent Application Serial No. 15/955,397, filed April 17, 2018 ("'397 Application")
1006	File History for Non-Provisional Patent Application Serial No. 15/955,397, filed April 17, 2018 ("'397 FH")
1007	File History for Non-Provisional Patent Application Serial No. 12/413,439, filed March 27, 2009 ("'439 FH") Part 1: Pages 1-400 Part 2: Pages 401-800 Part 3: Pages 801-1200 Part 4: Pages 1201-1600 Part 5: Pages 1601-2000 Part 6: Pages 2001-2400 Part 7: Pages 2401-2800 Part 8: Pages 2801-3200 Part 9: Pages 3201-3488
1008	Provisional Patent Application No. 61/040,558, filed March 28, 2008 ("'558 Provisional")
1009	Gwozdz et al., WO 2009/120933, Pharmaceutical Solutions And Method For Solubilizing Therapeutic Agents, published October 1, 2009, International Filing Date March 27, 2009 (PCT/US2009/038518) ("Gwozdz")
1010	Meezan et al., U.S. Patent Application Publication No. US 2006/0046962, Absorption Enhancers for Drug Administration, Serial No. 11/127,786, published March 2, 2006 ("Meezan")
1011	Ritschel, Handbook of Basic Pharmacokinetics, Chapter 36 (Bioavailability and Bioequivalence), Drug Intelligence Publications, Illinois, 1992 ("Ritschel")
1012	Osborne et al., Skin Penetration Enhancers Cited in the Technical Literature, Pharmaceutical Technology, November 1997 ("Osborne")

Exhibit No.	Description
1013	Lindhardt et al., Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers, Blackwell Science Ltd Br J Clin Pharmacol, 52, 521-527, 2001 ("Lindhardt")
1014	Illum L, Nasal drug delivery-possibilities, problems and solutions, Journal of Controlled Release 87 (2003) 187198 ("Illum I")
1015	Ivaturi et al., Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers, Acta Neurol Scand. 2009 Nov; 120(5):353-7. doi: 10.1111/j.1600-0404.2009.01170.x. Epub 2009 May 14 ("Ivaturi")
1016	Rowe et al., editors, Handbook of Pharmaceutical Excipients, Fourth Edition (2003), Monographs for "Alcohol" (i.e., ethanol), "Alpha Tocopherol", "Benzyl Alcohol", "Glycerin", "Olive Oil", "Polyethylene Glycol", "Propylene Glycol", "Sesame Oil", and "Triacetin", American Pharmaceutical Association, Washington DC ("Rowe")
1017	PDR 54th Edition 2000, DIASTAT® (diazepam rectal gel); MIACALCIN® (Calcitonin Nasal Spray); VALIUM® (diazepam injection), Physicians' Desk Reference ("PDR")
1018	Knoester PD, Jonker DM, Van Der Hoeven RT, et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002; 53: 501-507 ("Knoester")
1019	Florida Regional Common EMS Protocols Field Guide, Jones and Barlett Publishers, MA (2005) ("EMS")
1020	Valium® Tablet Label, Roche, January 2008 ("Valium label")
1021	Wolfe T, Macfarlane T. Intranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med 2006; 24:43-346 ("Wolfe")
1022	Holsti M, Sill B, Firth S, et al., Prehospital intranasal midazolam for the treatment of pediatric seizures. Ped Emerg Care 2007; 23: 148- 153 ("Holsti")
1023	Greenblatt D, Gan L, Harmatz, et al. Pharmacokinetics and pharmacodynamics of single-dose triazolam: EEG compared with digital symbol substitution test. Br J Clin Pharmacol 2005; 60: 244- 248 ("Greenblatt")

Exhibit No.	Description
1024	O'Regan M, Brown J, Clarke M. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures. Develop Med and Child Neurol 1996; 38: 1037-1045 ("O'Regan")
1025	Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatric Neurology 2006; 34: 355-359 ("Bhattacharyya")
1026	SIGMA Chemical Company Catalog (1988) ("Sigma Catalog")
1027	Wermeling DP, et al., Intranasal Delivery of Antiepileptic Medications for Treatment of Seizures, Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics, Vol. 6, 352-353, April 2009 ("Wermeling I")
1028	Hardman, et al., Editors, Goodman & Gilman's, The Pharmacological Basis of Therapeutics, 10th Edition (2001) ("Goodman & Gilman")
1029	Loftsson T, Gudmundsdottir H, Sigurjonsdittur JF, et al. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int J Pharm 2001; 212:29-40 ("Loftsson")
1030	Gudmundsdottir H, Sigurjonsdottir JF, Masson M, et al. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie 2001; 56: 963-966 ("Gudmundsdottir")
1031	Dale O., Nilsen T., Loftsson T. Intranasal midazolam: a comparison of two delivery devices in human volunteers. J Pharmacy Pharmacol 2006; 58: 1311-1318 ("Dale")
1032	Burstein AH, Modica R, Hatton M, et al. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. J Clin Pharmacol 1997; 37: 711-718 ("Burstein")
1033	Wermeling, D, Record K, Kelly T, et al., Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesth Analg 2006; 103:344-349 ("Wermeling II")
1034	Schols-Hendriks MWG, Lohman JJHM, Janknegt R, et al. Absorption of clonazepam after intranasal and buccal administration. Br J Clin Pharmacol, 1995; 39: 449-451 ("Schols-Hendricks")

Exhibit No.	Description
1035	Lau SWJ, Slattery JT. Intl J Pharmaceutics. Absorption of diazepam and lorazepam following intranasal administration. Int J Pharmaceutics 1989; 54: 171-174 ("Lau")
1036	Wermeling DP, Miller JL, Archer SM, et al. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol, 2001; 41: 1225-1231 ("Wermeling III")
1037	Budavari, et al., Editors, The Merck Index, 12th Edition (1996) ("Merck Index")
1038	USP 26/NF 21 2003, The Official Compendia of Standards, Ethanol, Copyright 2002 ("USP 26/ NF 21")
1039	U.S. App. No. 12/413,439, filed March 27, 2009 ("'439 Application")
1040	Final Written Decision issued in IPR 2019-00451 filed against U.S. Written Decision")
1041	Lowenstein DH, Alldredge BK. Status epilepticus, N Eng J Med 1998; 338:970-976 ("Lowenstein I")
1042	Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999: 40:120-122 ("Lowenstein II")
1043	Wang HC, Chang WN, Chang HW, et al., Factors predictive of outcome in postraumatic seizures. J Trauma 2008; 64: 883-888 ("Wang")
1044	Stavem K, Bjornaes H, Langmoen IA. Long-term seizures and quality of life after epilepsy surgery compared with matched controls. Neurosurgery 2008; 62: 326-334 ("Stavem")
1045	Logroscino G, Hessdorffer DC, Cascino G, et al., Time Trends in incidence, mortality, and case-fatality after first episode of status epilepticus, Epilepsia 2001; 42:1031-1035 ("Logroscino")
1046	Feen ES, Bershad EM, Suarez JI, Status Epilepticus, South Med J 2008; 101: 400-406 ("Feen")
1047	Pang T, Hirsch L, Treatment of convulsive and nonconvulsive status epilepticus, Cur Treat Options Neurol 2005; 7:247-259 ("Pang")

Exhibit No.	Description
1048	Smith B, Treatment of status epilepticus, Neurol Clin 2001; 19:347- 369 ("Smith")
1049	Ericksson K, Kalviainen R. Pharmacologic management of convulsive status epilepticus in childhood, Expert Rev Neurotherapeutics 2005; 5:777-783 ("Ericksson")
1050	Meierkord H, Engelsen B, Gocke K, et al., EFNS guideline on the management of status epilepticus, Eur J Neurol 2006; 13: 445-450 ("Meierkord")
1051	Prasad K, Krishman P, Al-Roomi K, et al., Anticonvulsant therapy for status epilepticus, Br J Clin Pharmacol 2007; 63:640-647 ("Prasad")
1052	Illum L., Nasal Clearance in Health and Disease, J Aerosol Med 2006; 19:92-99 ("Illum II")
1053	Constantino HR, Illum L, Brandt G et al., Intranasal delivery: Physicochemical and therapeutic aspects, Intl J Pharmaceutics 2007; 337:1-24 ("Constantino")
1054	Rudy AC, Coda BA, Archer SM, et al., A multiple dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers, Anesth Analg 2004; 99:1379-1386 ("Rudy")
1055	Mittal P, Manohar R, Rawat A, Comparative study of intranasal midazolam and intravenous diazepam sedation for procedures and seizures, Ind J Pediatrics 2006; 73:975-78 ("Mittal")
1056	Mahmoudian T, Zadeh M, Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children, Epilepsy and Behavior 2004; 5:253-255 ("Mahmoudian")
1057	Lahat E, Goldman M, Barr J, et al., Comparison of intranasal midazolam with intravenous diazepam in treating febrile seizures in children: prospective randomized study, BMJ 2000; 321:83-87 ("Lahat")
1058	Sharma S, et al., Permeation enhancers in the transmucosal delivery of macromolecules, Pharmazie 2006; 61(6): 495-504 ("Sharma")
1059	Ahsan F. et al., Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-β-cyclodextrin, on insulin

Exhibit No.	Description
	movement across human bronchial epithelial cells, Eur J Pharm Sciences 2003; 20:27-34 ("Ahsan").
1060	U.S. Patent No. 5,661,130 to Meezan and Pillion ("Meezan II")
1061	U.S. Patent No. 6,610,271 to Wermeling ("Wermeling IV")
1062	Declaration of Dr. Maureen Donovan, Ph.D.
1063	Complaint filed in Neurelis, Inc. v. Padagis LLC et al., Civil Action No. 1:24-cv-11637 (D. Mass) (complaint filed on June 25, 2024).
1064	U.S. Provisional Patent App. No. 61/040,281 ("'281 Provisional")
1065	U.S. Publication No. 2008/0279784 to Cartt et al. ("Cartt")
1066	USP 23/NF 18 1995, The Official Compendia of Standards, Vitamin E, Copyright 1994 ("USP 23/NF 18")
1067	U.S. Provisional Patent App. No. 60/916,550 ("'550 Provisional")
1068	Neurelis, Inc. v. Aquestive Therapeutics, Inc., No. 2021-1038, (Fed. Cir. Oct. 7, 2021)
1069	Chart comparing claims 1-27 of the '786 Patent to claims 1-36 of the '876 Patent
1070	Declaration of Chad Landmon in Support of Being a Provisionally Recognized PTAB Attorney
1071	US Patent No. 9,763,876 to Cartt ("'876 Patent")
1072	Expert Declaration of Professor Sveinbjorn Gizurarson in Support of Patent Owner's Response to Petition for *Inter Partes* Review of U.S. Patent No. 9,763,876
1073	Lim et al., *Physiological Factors Affecting Nasal Drug Delivery*, *in* ENHANCEMENT IN DRUG DELIVERY (Elka Touitou & Brian W. Barry, 2007)
1074	US Patent No. 6,962,691 to Lulla
1075	File History for Non-Provisional Patent Application Serial No. 11/127,786, Response to Office Action and Amendments filed August 13, 2007
1076	File History for Non-Provisional Patent Application Serial No. 13/371,274, Declaration of Dr. Edward T. Maggio filed September 19, 2013

Exhibit No.	Description
1077	Certified Transcript of Deposition of Marc Brown, Ph.D. in *Padagis US LLC vs. Neurelis, Inc.*, IPR2025-00464, IPR2025-00465, IPR2025-00466 (March 17, 2026)
1078	Supplemental Declaration of Dr. Maureen Donovan
1079	Panico et al., A GUIDE TO IUPAC NOMENCLATURE OF ORGANIC COMPOUNDS, Recommendations (1993) ("IUPAC")
1080	US Patent No. 8,278,292 to Brown ("'292 Patent")
1081	Appellant Neurelis Inc.'s Opening Brief, *Neurelis, Inc. v. Aquestive Therapeutics, Inc.*, No. 2021-1038 (Fed. Cir. Feb. 2, 2021).
1082	Appellant Neurelis Inc.'s Reply Brief, *Neurelis, Inc. v. Aquestive Therapeutics, Inc.*, No. 2021-1038 (Fed. Cir. Feb. 2, 2021).
1083	Stipulation Regarding Claim Construction, *Neurelis, Inc. v. Padagis LLC et al.*, 1-24-cv-00562 (D.Del. May 8, 2024).
1084	USPTO Assignment Record of US Pub. No. 2008/0279784 to Cartt
1085	USPTO Assignment Record of the '786 Patent
1086	USPTO Assignment Record of U.S. Patent Application 12/413,439
1087	Federal Register Volume 61, Number 27, Pages 4822-23 (February 8, 1996)
1088	US Patent No. 6,383,513 to Watts
1089	USPTO Assignment Document for U.S. Patent Application 12/413,439 Recorded on June 30, 2009 at Reel/Frame 022897/0583
1090	Email from Murphy to Tobin (Jan. 20, 2026)
1091	Email from Tobin to Murphy (Feb. 2, 2026)
1092	Email from Murphy to Tobin (Feb. 4, 2026)
1093	Email from Tobin to Murphy (Feb. 10, 2026)
1094	Email from Murphy to Tobin (Feb. 12, 2026)
1095	Email from Murphy to Tobin (Feb. 18, 2026)
1096	Email from Sitzman to Murphy (Feb. 19, 2026)
1097	Email from Murphy to Sitzman (Feb. 23, 2026)
1098	Email from Sitzman to Murphy (Feb. 25, 2026)
1099	Email from Tobin to Murphy (March 25, 2026)
1100	Email from Murphy to Tobin (March 26, 2026)

Exhibit No.	Description
1101	Email from Tobin to Murphy (March 27, 2026)
1102	Email from Deming to Sitzman (March 10, 2026)
1103	Email from Deming to Sitzman (June 16, 2025)
1104	File History for Non-Provisional Patent Application Serial No. 11/127,786
1105	Joint Claim Construction Chart (filed on June 1, 2026)
1106	Defendants' Proposed Claim Terms and Phrases for Construction (served on May 15, 2026)
1107	Defendants' Preliminary Invalidity Contentions (served on May 8, 2026)

Dated: June 10, 2026

Respectfully submitted,

/James P. Murphy/

James P. Murphy
Reg. No. 55,474
Polsinelli PC
1000 Louisiana Street
Suite 6400
Houston, Texas 77002
Tel: (713) 374-1600

Corey Casey
Reg. No. 66,950
Polsinelli PC
900 West 48th Place
Suite 900
Kansas City, Missouri 64112
Tel: (816) 572-4439

Mark Deming
Registration No. 69,263
Polsinelli PC
150 N. Riverside Plaza
Suite 3000
Chicago, Illinois 60606

Tel: (314) 873-3607

Christopher Jones
Registration No. 76,472
Polsinelli PC
1401 Eye Street N.W.
Suite 800
Washington, D.C. 20005
Tel: (202) 626-8358

Chad Landmon
pro hac vice
Polsinelli PC
1401 Eye Street N.W.
Suite 800
Washington, D.C. 20005
Tel: (206) 626-8303

Attorneys for Petitioner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6(e)(4)(i) *et seq.* and 42.105(b), the undersigned certifies that a complete copy of the forgoing document and all associated exhibits are being served via electronic mail on June 10, 2026 upon the following:

Michael Sitzman
msitzman@mwe.com

Timothy P. Best
tbest@mwe.com

David J. Tobin
dtobin@mwe.com

Hannah Hurley
hhurley@mcdermottlaw.com

Raymond Miller
raymond.miller@us.dlapiper.com

N. Nicole Endejann
nicole.endejann@us.dlapiper.com

neurelis-ptab@mwe.com

/Ericka McNeil/
Ericka McNeil
Polsinelli, PC
1000 Louisiana Street, Suite 6400
Houston, Texas 77002
Tele: (713) 374-1600